Caveolinopathies. translational implications of caveolin-3 in skeletal and cardiac muscle disorders

Handbook of Clinical Neurology

Volumn 101, Issue , 2011, Pages 135-142

  Gazzerro, E ^a   Bonetto, A ^a   Minetti, C ^a  

^a G GASLINI INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CAV3 PROTEIN, HUMAN; CAVEOLIN 3;

BOOK; GENETICS; HEART MUSCLE; HUMAN; METABOLISM; MUSCLE DISEASE; MUTATION; PATHOLOGY; SKELETAL MUSCLE;

CAVEOLIN 3; HUMANS; MUSCLE, SKELETAL; MUSCULAR DISEASES; MUTATION; MYOCARDIUM;

EID: 79954485568     PISSN: 00729752     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-08-045031-5.00010-4     Document Type: Book

References (59)

1. Alias L., Gallano P., Moreno D., et al. A novel mutation in the caveolin-3 gene causing familial isolated hyperCKaemia. Neuromuscul Disord 2004, 14:321-324.
2. Aravamudan B., Volonte D., Ramani R., et al. Transgenic overexpression of caveolin-3 in the heart induces a cardiomyopathic phenotype. Hum Mol Genet 2003, 12:2777-2788.
3. Bae J.S., Ki C.S., Kim J.W., et al. A novel in-frame deletion in the CAV3 gene in a Korean patient with rippling muscle disease. J Neurol Sci 2007, 260:275-278.
4. Barbuti A., Terragni B., Brioschi C., et al. Localization of f-channels to caveolae mediates specific beta2-adrenergic receptor modulation of rate in sinoatrial myocytes. J Mol Cell Cardiol 2007, 42:71-78.
5. Bastiani M., Liu L., Hill M.M., et al. MURC/Cavin-4 and cavin family members form tissue-specific caveolar complexes. J Cell Biol 2009, 185:1259-1273.
6. Betz R.C., Schoser B.G., Kasper D., et al. Mutations in CAV3 cause mechanical hyperirritability of skeletal muscle in rippling muscle disease. Nat Genet 2001, 28:218-219.
7. Cagliani R., Bresolin N., Prelle A., et al. A CAV3 microdeletion differentially affects skeletal muscle and myocardium. Neurology 2003, 61:1513-1519.
8. Carbone I., Bruno C., Sotgia F., et al. Mutation in the CAV3 gene causes partial caveolin-3 deficiency and hyperCKemia. Neurology 2000, 54:1373-1376.
9. Catteruccia M., Sanna T., Santorelli F.M., et al. Rippling muscle disease and cardiomyopathy associated with a mutation in the CAV3 gene. Neuromuscul Disord 2009, 19:779-783.
10. Cronk L.B., Ye B., Kaku T., et al. Novel mechanism for sudden infant death syndrome: persistent late sodium current secondary to mutations in caveolin-3. Heart Rhythm 2007, 4:161-166.
11. Dotti M.T., Malandrini A., Gambelli S., et al. A new missense mutation in caveolin-3 gene causes rippling muscle disease. J Neurol Sci 2006, 243:61-64.
12. Fanzani A., Stoppani E., Gualandi L., et al. Phenotypic behavior of C2C12 myoblasts upon expression of the dystrophy-related caveolin-3 P104L and TFT mutants. FEBS Lett 2007, 581:5099-5104.
13. Fee D.B., So Y.T., Barraza C., et al. Phenotypic variability associated with Arg26Gln mutation in caveolin3. Muscle Nerve 2004, 30:375-378.
14. Figarella-Branger D., Pouget J., Bernard R., et al. Limb-girdle muscular dystrophy in a 71-year-old woman with an R27Q mutation in the CAV3 gene. Neurology 2003, 61:562-564.
15. Fischer D., Schroers A., Blümcke I., et al. Consequences of a novel caveolin-3 mutation in a large German family. Ann Neurol 2003, 53:233-241.
16. Fulizio L., Nascimbeni A.C., Fanin M., et al. Molecular and muscle pathology in a series of caveolinopathy patients. Hum Mutat 2005, 25:82-89.
17. Galbiati F., Volonte D., Minetti C., et al. Phenotypic behavior of caveolin-3 mutations that cause autosomal dominant limb girdle muscular dystrophy (LGMD-1C). Retention of LGMD-1C caveolin-3 mutants within the golgi complex. J Biol Chem 1999, 274:25632-25641.
18. Galbiati F., Engelman J.A., Volonte D., et al. Caveolin-3 null mice show a loss of caveolae, changes in the microdomain distribution of the dystrophin-glycoprotein complex, and t-tubule abnormalities. J Biol Chem 2001, 276:21425-21433.
19. Galbiati F., Razani B., Lisanti M.P. Caveolae and caveolin-3 in muscular dystrophy. Trends Mol Med 2001, 7:435-441.
20. Gazzerro E., Sotgia F., Bruno C., et al. Caveolinopathies: from the biology of caveolin-3 to human diseases. Eur J Hum Genet 2010, 18:137-145.
21. González-Pérez P., Gallano P., González-Quereda L., et al. Phenotypic variability in a Spanish family with a Caveolin-3 mutation. J Neurol Sci 2009, 276:95-98.
22. Guglieri M., Magri F., D'Angelo M.G., et al. Clinical, molecular, and protein correlations in a large sample of genetically diagnosed Italian limb girdle muscular dystrophy patients. Hum Mutat 2008, 29:258-266.
23. Hayashi T., Arimura T., Ueda K., et al. Identification and functional analysis of a caveolin-3 mutation associated with familial hypertrophic cardiomyopathy. Biochem Biophys Res Commun 2004, 313:178-184.
24. Hayashi Y.K., Matsuda C., Ogawa M., et al. Human PTRF mutations cause secondary deficiency of caveolins resulting in muscular dystrophy with generalized lipodystrophy. J Clin Invest 2009, 119:2623-2633.
25. Hernández-Deviez D.J., Martin S., Laval S.H., et al. Aberrant dysferlin trafficking in cells lacking caveolin or expressing dystrophy mutants of caveolin-3. Hum Mol Genet 2006, 15:129-142.
26. Hill M.M., Bastiani N., Luetterforst R., et al. PTRF-Cavin, a conserved cytoplasmic protein required for caveola formation and function. Cell 2008, 132:113-124.
27. Hnasko R., Lisanti M.P. The biology of caveolae: lessons from caveolin knockout mice and implications for human disease. Mol Interv 2003, 3:445-464.
28. Kikuchi T., Oka N., Koga A., et al. Behavior of caveolae and caveolin-3 during the development of myocyte hypertrophy. J Cardiovasc Pharmacol 2005, 45:204-210.
29. Koga A., Oka N., Kikuchi T., et al. Adenovirus-mediated overexpression of caveolin-3 inhibits rat cardiomyocyte hypertrophy. Hypertension 2003, 42:213-219.
30. Kubisch C., Schoser B.G., von Düring M., et al. Homozygous mutations in caveolin-3 cause a severe form of rippling muscle disease. Ann Neurol 2003, 53:512-520.
31. Kunkel L. Caveolin-3 deficiency as a cause of limb-girdle muscular dystrophy. J Child Neurol 1999, 14:33-34.
32. Lorenzoni P.J., Scola R.H., Vieira N., et al. A novel missense mutation in the caveolin-3 gene in rippling muscle disease. Muscle Nerve 2007, 36:258-260.
33. Madrid R.E., Kubisch C., Hays A.P. Early-onset toe walking in rippling muscle disease due to a new caveolin-3 gene mutation. Neurology 2005, 65:1301-1303.
34. + channels to distinct lipid raft populations. Targeting of Kv1.5 to caveolae. J Biol Chem 2001, 276:8409-8414.
35. Matsuda C., Hayashi Y.K., Ogawa M., et al. The sarcolemmal proteins dysferlin and caveolin-3 interact in skeletal muscle. Hum Mol Genet 2001, 10:1761-1766.
36. Mercier I., Jasmin J.F., Pavlides S., et al. Clinical and translational implications of the caveolin gene family: lessons from mouse models and human genetic disorders. Lab Invest 2009, 89:614-623.
37. Merlini L., Carbone I., Capanni C., et al. Familial isolated hyperCKaemia associated with a new mutation in the caveolin-3 (CAV-3) gene. J Neurol Neurosurg Psychiatry 2002, 73:65-67.
38. Minetti C., Sotgia F., Bruno C., et al. Mutations in the caveolin-3 gene cause autosomal dominant limb-girdle muscular dystrophy. Nat Genet 1998, 18:365-368.
39. Minetti C., Bado M., Broda P., et al. Impairment of caveolae formation and T-system disorganization in human muscular dystrophy with caveolin-3 deficiency. Am J Pathol 2002, 160:265-270.
40. Nixon S.J., Wegner J., Ferguson C., et al. Zebrafish as a model for caveolin-associated muscle disease; caveolin-3 is required for myofibril organization and muscle cell patterning. Hum Mol Genet 2005, 14:1727-1743.
41. Ohsawa Y., Toko H., Katsura M., et al. Overexpression of P104L mutant caveolin-3 in mice develops hypertrophic cardiomyopathy with enhanced contractility in association with increased endothelial nitric oxide synthase activity. Hum Mol Genet 2004, 13:151-157.
42. Parton R.G. Caveolae and caveolins. Curr Opin Cell Biol 1996, 8:542-548.
43. Reijneveld J.C., Ginjaar I.B., Frankhuizen W.S., et al. CAV3 gene mutation analysis in patients with idiopathic hyper-CK-emia. Muscle Nerve 2006, 34:656-658.
44. Schara U., Vorgerd M., Popovic N., et al. Rippling muscle disease in childhood. J Child Neurol 2002, 17:483-490.
45. Schubert W., Sotgia F., Cohen A.W., et al. Caveolin-1(-/-)- and caveolin-2(-/-)-deficient mice both display numerous skeletal muscle abnormalities, with tubular aggregate formation. Am J Pathol 2007, 170:316-333.
46. Serra M., Scotlandi K. Caveolins in the development and diseases of musculoskeletal system. Cancer Lett 2009, 284:113-121.
47. Smythe G.M., Rando T.A. Altered caveolin-3 expression disrupts PI(3) kinase signaling leading to death of cultured muscle cells. Exp Cell Res 2006, 312:2816-2825.
48. Smythe G.M., Eby J.C., Disatnik M.H., et al. A caveolin-3 mutant that causes limb girdle muscular dystrophy type 1C disrupts Src localization and activity and induces apoptosis in skeletal myotubes. J Cell Sci 2003, 116:4739-4749.
49. Sugie K., Murayama K., Noguchi S., et al. Two novel CAV3 gene mutations in Japanese families. Neuromuscul Disord 2004, 14:810-814.
50. Sunada Y., Ohi H., Hase A., et al. Transgenic mice expressing mutant caveolin-3 show severe myopathy associated with increased nNOS activity. Hum Mol Genet 2001, 10:173-178.
51. Tateyama M., Aoki M., Nishino I., et al. Mutation in the caveolin-3 gene causes a peculiar form of distal myopathy. Neurology 2002, 58:323-325.
52. Traverso M., Gazzerro E., Assereto S., et al. Caveolin-3 T78M and T78K missense mutations lead to different phenotypes in vivo and in vitro. Lab Invest 2008, 88:275-283.
53. Van den Bergh P.Y., Gérard J.M., Elosegi J.A., et al. Novel missense mutation in the caveolin-3 gene in a Belgian family with rippling muscle disease. J Neurol Neurosurg Psychiatry 2004, 75:1349-1351.
54. Vatta M., Ackerman M.J., Ye B., et al. Mutant caveolin-3 induces persistent late sodium current and is associated with long-QT syndrome. Circulation 2006, 114:2104-2112.
55. Volonte D., Liu Y., Galbiati F. The modulation of caveolin-1 expression controls satellite cell activation during muscle repair. FASEB J 2005, 19:237-239.
56. Vorgerd M., Ricker K., Ziemssen F., et al. A sporadic case of rippling muscle disease caused by a de novo caveolin-3 mutation. Neurology 2001, 57:2273-2277.
57. Williams T.M., Lisanti M.O. The Caveolin genes: from cell biology to medicine. Ann Med 2004, 36:584-595.
58. Woodman S.E., Sotgia F., Galbiati F., et al. Caveolinopathies: mutations in caveolin-3 cause four distinct autosomal dominant muscle diseases. Neurology 2004, 62:538-543.
59. Yarbrough T.L., Lu T., Lee H.C., et al. Localization of cardiac sodium channels in caveolin-rich membrane domains: regulation of sodium current amplitude. Circ Res 2002, 90:443-449.